Keyword Tag Sort by

Pancreatic neuroendocrine tumors News (3 articles)

Novartis gains FDA approval for Afinitor® as first new treatment in nearly three decades for patients with advanced pancreatic NET

Data show Afinitor delays tumor growth and reduces risk of disease progression in patients with advanced neuroendocrine tumors (NET) of pancreatic origin[1] Afinitor represents a new approach to treat advanced pancreatic NET, an aggressive cancer for which there has been...

Published on 6 May 2011, 05:14

Novartis drug Afinitor® recommended by FDA oncology advisory committee for approval to treat advanced NET of pancreatic origin

Committee votes unanimously in favor of everolimus to treat patients with advanced neuroendocrine tumors (NET) of pancreatic origin Phase III results showed everolimus more than doubled median progression-free survival from 4.6 to 11.0 months when compared with placebo in...

Published on 12 April 2011, 18:57

Afinitor® and Sandostatin® LAR® Phase II data show advanced pancreatic NET patients remain progression-free for nearly 17 months

. 84% of patients with advanced pancreatic neuroendocrine tumors (NET) who took Afinitor® combined with Sandostatin® LAR® experienced tumor shrinkage. Patients with this rare and aggressive form of cancer have limited treatment options following chemotherapy. Phase III trial of...

Published on 24 June 2009, 13:48